Townsquare Capital LLC raised its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 34.3% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 549,692 shares of the biopharmaceutical company's stock after purchasing an additional 140,342 shares during the quarter. Townsquare Capital LLC's holdings in Pfizer were worth $13,929,000 as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. Clarity Asset Management Inc. acquired a new stake in shares of Pfizer in the 4th quarter valued at $27,000. Gould Capital LLC boosted its holdings in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 493 shares in the last quarter. Bayforest Capital Ltd acquired a new stake in shares of Pfizer during the 1st quarter valued at $28,000. North Capital Inc. acquired a new stake in shares of Pfizer during the 1st quarter valued at $28,000. Finally, Bernard Wealth Management Corp. acquired a new stake in shares of Pfizer during the 4th quarter valued at $30,000. Institutional investors and hedge funds own 68.36% of the company's stock.
Pfizer Stock Up 1.4%
Shares of PFE opened at $24.57 on Friday. The stock's 50-day moving average price is $24.44 and its two-hundred day moving average price is $24.50. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The company has a current ratio of 1.16, a quick ratio of 0.96 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $139.69 billion, a PE ratio of 13.07, a PEG ratio of 0.87 and a beta of 0.52.
Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. The firm had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same period last year, the company posted $0.60 EPS. The business's quarterly revenue was up 10.3% on a year-over-year basis. On average, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.
Pfizer Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. Pfizer's dividend payout ratio (DPR) is 91.49%.
Analyst Ratings Changes
PFE has been the topic of several recent research reports. Redburn Atlantic cut their price objective on Pfizer from $29.00 to $27.00 and set a "neutral" rating on the stock in a report on Wednesday, April 30th. Cantor Fitzgerald initiated coverage on Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective on the stock. TD Cowen cut their price objective on Pfizer from $32.00 to $28.00 and set a "hold" rating on the stock in a report on Tuesday, April 22nd. Morgan Stanley raised their price objective on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday. Finally, UBS Group raised their price objective on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $28.12.
Get Our Latest Research Report on Pfizer
Pfizer Company Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
See Also
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
